No preview available from this publisher — open the full story below.
Analysts have trimmed their price targets for Exagen (XGN) stock, leading to a split in fresh price target recommendations. This development suggests a cautious outlook among some market observers regarding the company's future performance. Investors are now evaluating the…
Market Samachar is a news aggregator. This article was originally published by Simply Wall St.. Tap the button above to read the full story on their site.